Development
Dyne Therapeutics, Inc.
DYN
$11.59
$1.1210.70%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -71.63% | -45.49% | -24.09% | -24.18% | 25.02% |
| Total Depreciation and Amortization | -0.50% | 8.56% | -6.30% | -3.06% | 17.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.87% | 40.11% | 1.31% | -22.32% | -32.48% |
| Change in Net Operating Assets | 395.13% | 187.29% | -74.34% | 63.57% | -70.26% |
| Cash from Operations | -19.92% | -18.22% | -80.02% | 7.55% | -4.00% |
| Capital Expenditure | 84.20% | 81.15% | 4.21% | 83.58% | 73.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.01% | -75.28% | -6.53% | 3,813.20% | 1,025.70% |
| Cash from Investing | 36.18% | -75.18% | -6.57% | 1,366.95% | 8,285.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.60% | 548.57% | 25,057.58% | 159,983.33% | 41,701.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.60% | 548.57% | 25,057.58% | 159,983.33% | 41,701.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -131.79% | -518.32% | -9.19% | 116.97% | 196.58% |